Will any FDA-approved GLP-1 agonists be withdrawn from the market for safety reasons by 01/01/2025?
12
55
Ṁ697Ṁ288
2025
15%
chance
1D
1W
1M
ALL
GLP-1 agonists, such as semaglutide (ozempic/wegovy), tirzepatide (mounjaro), and dulaglutide (Trulicity), are becoming popular for weight loss and Type-2 diabetes treatment. This market resolves positively if any approved GLP-1 agonists for either T2D or weight loss are withdrawn from the market due to safety reasons by the listed date. This applies either if the FDA mandates it or if the company withdraws the drug voluntarily.
Get Ṁ1,000 play money
Sort by:
made a market that breaks this out by end year and added a M5k subsidy: https://manifold.markets/AndyMartin/m5k-subsidy-will-any-fdaapproved-gl
More related questions
Related questions
Will GiveWell fund Attractive toxic sugar baits for malaria control by 1st January 2027?
32% chance
Will AOH1996 be FDA approved before 2040?
45% chance
Will a senolytic drug be used clinically to slow, prevent, or reverse aging by the end of 2033?
43% chance
[M$5k subsidy] Will any FDA-approved GLP-1 agonists be withdrawn from the market for safety reasons by...